Envestnet Asset Management Inc. Purchases 5,794 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Asset Management Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 10.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 63,483 shares of the biopharmaceutical company’s stock after purchasing an additional 5,794 shares during the period. Envestnet Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $55,757,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cibc World Markets Corp increased its position in shares of Regeneron Pharmaceuticals by 117.4% during the fourth quarter. Cibc World Markets Corp now owns 39,496 shares of the biopharmaceutical company’s stock valued at $34,689,000 after acquiring an additional 21,325 shares during the last quarter. Gabelli Funds LLC increased its position in shares of Regeneron Pharmaceuticals by 16.5% during the 4th quarter. Gabelli Funds LLC now owns 1,805 shares of the biopharmaceutical company’s stock valued at $1,585,000 after purchasing an additional 255 shares during the last quarter. Public Employees Retirement Association of Colorado increased its position in shares of Regeneron Pharmaceuticals by 16.0% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock valued at $14,118,000 after purchasing an additional 2,220 shares during the last quarter. 1832 Asset Management L.P. raised its stake in shares of Regeneron Pharmaceuticals by 18.6% during the 4th quarter. 1832 Asset Management L.P. now owns 2,254 shares of the biopharmaceutical company’s stock worth $1,980,000 after purchasing an additional 353 shares during the period. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 10.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 12,128 shares of the biopharmaceutical company’s stock worth $10,652,000 after buying an additional 1,139 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $1,001.73 on Tuesday. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $110.38 billion, a P/E ratio of 29.59, a PEG ratio of 2.07 and a beta of 0.13. The stock has a 50-day moving average price of $949.97 and a 200-day moving average price of $930.22. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $1,016.00.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Bank of America raised their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. UBS Group boosted their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Finally, Royal Bank of Canada boosted their price objective on Regeneron Pharmaceuticals from $1,185.00 to $1,200.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. One analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $989.86.

Check Out Our Latest Research Report on REGN

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the completion of the sale, the chief executive officer now owns 64,198 shares of the company’s stock, valued at approximately $65,162,253.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold a total of 56,399 shares of company stock worth $55,145,791 in the last 90 days. 7.48% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.